♥
ISIN : INE904D01019
NSE : PDPL
BSE : 524689
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : -25.61
EPS (TTM) : -25.61
Price to Earning (P/E) : -0.13
Book Value : -253.19
Price to Bookvalue (P/B) : -0.01
Dividend Yield : 0 %
Return on Equity (ROE) : %
Return on Capital Employed (ROCE) : %
Parenteral Drugs (India) Limited
ISIN : INE904D01019
NSE : PDPL
BSE : 524689
Face Value : 10
Industry : Pharmaceuticals & Drugs
EPS : -25.61
EPS (TTM) : -25.61
Price to Earning (P/E) : -0.13
Book Value : -253.19
Price to Bookvalue (P/B) : -0.01
Dividend Yield : 0 %
Return on Equity (ROE) : %
Return on Capital Employed (ROCE) : %
Parenteral Drugs share price(21-Aug-2023) | |
|---|---|
| Open / Close | 0 - 0 NAN % |
| Low / High | 0 - 0 NAN % |
| Trade Volume | 0 |
| 52 Week Low / High | 0 - 0 NAN % |
| Open / Close | 3.08 - 3.39 10.1 % |
| Low / High | 3.08 - 3.39 10.1 % |
| Trade Volume | 1,250 |
| 52 Week Low / High | 0 - 0 NAN % |
-
YOU MAY ALSO LIKE
- Share Market basics for beginners
Share Market jargons in simple terms - Stock market course tutorial
Stock Market Investment Course explained in simple words. - High dividend stocks
High dividend yield stocks on Stock exchange NSE and BSE - Low PE ratio stocks
Undervalued, low PE ratio stocks on Stock exchange NSE and BSE - CAGR Calculator
Check your investment returns using our CAGR / Investment Growth Calculator - How much money do you need to retire
Know how much money do you need to retire, before how much to invest ?
CONSOLIDATED QUARTERLY RESULT FOR PARENTERAL DRUGS (INDIA) LIMITED
| Date End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 29.31 | 23.5 | 14.42 | 18.13 |
| Total Income | 29.41 | 23.61 | 14.53 | 18.13 |
| Total Expenditure | 61.93 | 56.2 | 46.67 | 76.59 |
| Other Income | 0.11 | 0.11 | 0.11 | |
| Operating Profit | -32.52 | -32.59 | -32.14 | -58.46 |
| Interest | 340.97 | 354.65 | 366.83 | 0.01 |
| Exceptional Items | 522.11 | |||
| PBDT | -373.49 | -387.24 | -398.97 | 463.64 |
| Depreciation | 37.05 | 43.31 | 43.32 | 271.53 |
| Profit Before Tax | -410.54 | -430.55 | -442.29 | 192.11 |
| Tax | -90.16 | -94.41 | -97.04 | -46.02 |
| Profit After Tax | -320.38 | -336.14 | -345.25 | 238.13 |
| Net Profit | -320.38 | -336.14 | -345.25 | 238.13 |
| Equity Capital | 298.16 | 298.16 | 298.16 | 298.16 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 |
| Calculated EPS | -10.74 | -11.27 | -11.58 | 7.99 |
| Diluted Eps After Extraordinary Items | -10.74 | -11.28 | -11.58 | 7.99 |
| Diluted Eps Before Extraordinary Items | -10.74 | -11.28 | -11.58 | 7.99 |
STANDALONE QUARTERLY RESULT FOR PARENTERAL DRUGS (INDIA) LIMITED
| Date End | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
|---|---|---|---|---|
| No of months | 3 months | 3 months | 3 months | 3 months |
| Net Sales | 29.41 | 23.61 | 14.53 | 18.13 |
| Total Income | 29.41 | 23.61 | 14.53 | 18.13 |
| Total Expenditure | 55.66 | 56.2 | 46.67 | 76.59 |
| Operating Profit | -26.25 | -32.59 | -32.14 | -58.46 |
| Interest | 340.97 | 354.65 | 366.83 | 0.01 |
| Exceptional Items | 522.11 | |||
| PBDT | -367.22 | -387.24 | -398.97 | 463.64 |
| Depreciation | 43.32 | 43.31 | 43.32 | 271.53 |
| Profit Before Tax | -410.54 | -430.55 | -442.29 | 192.11 |
| Tax | -90.16 | -94.41 | -97.04 | -46.03 |
| Profit After Tax | -320.38 | -336.14 | -345.25 | 238.14 |
| Net Profit | -320.38 | -336.14 | -345.25 | 238.14 |
| Equity Capital | 298.16 | 298.16 | 298.16 | 298.16 |
| Face Value (IN RS) | 10 | 10 | 10 | 10 |
| Calculated EPS | -10.75 | -11.27 | -11.58 | 7.99 |
| Diluted Eps After Extraordinary Items | -10.74 | -11.28 | -11.58 | 7.99 |
| Diluted Eps Before Extraordinary Items | -10.74 | -11.28 | -11.58 | 7.99 |
CONSOLIDATED ANNUAL RESULT FOR PARENTERAL DRUGS (INDIA) LIMITED
| Date End | Mar 2022 |
|---|---|
| No of months | 12 months |
| Net Sales | 85.68 |
| Total Income | 85.68 |
| Total Expenditure | 235.1 |
| Operating Profit | -149.42 |
| Interest | 1062.47 |
| Exceptional Items | 522.11 |
| PBDT | -689.78 |
| Depreciation | 401.48 |
| Profit Before Tax | -1091.26 |
| Tax | -327.64 |
| Profit After Tax | -763.62 |
| Net Profit | -763.62 |
| Equity Capital | 298.16 |
| Face Value (IN RS) | 10 |
| Calculated EPS | -25.61 |
| Diluted Eps After Extraordinary Items | -25.61 |
| Diluted Eps Before Extraordinary Items | -25.61 |
STANDALONE ANNUAL RESULT FOR PARENTERAL DRUGS (INDIA) LIMITED
| Date End | Mar 2022 |
|---|---|
| No of months | 12 months |
| Net Sales | 85.68 |
| Total Income | 85.68 |
| Total Expenditure | 235.09 |
| Operating Profit | -149.41 |
| Interest | 1062.47 |
| Exceptional Items | 522.11 |
| PBDT | -689.77 |
| Depreciation | 401.48 |
| Profit Before Tax | -1091.25 |
| Tax | -327.64 |
| Profit After Tax | -763.61 |
| Net Profit | -763.61 |
| Equity Capital | 298.16 |
| Face Value (IN RS) | 10 |
| Calculated EPS | -25.61 |
| Diluted Eps After Extraordinary Items | -25.61 |
| Diluted Eps Before Extraordinary Items | -25.61 |
CONSOLIDATED PROFIT / LOSS FOR PARENTERAL DRUGS (INDIA) LIMITED
| YEAR | Mar 2021 |
|---|---|
| No of Months | 12 months |
| Gross Sales | 12.17 Cr |
| Sales | 7.82 Cr |
| Job Work/ Contract Receipts | 4.33 Cr |
| Net Sales | 12.17 Cr |
| Increase/Decrease in Stock | -61.54 Lk |
| Raw Material Consumed | 6.28 Cr |
| Opening Raw Materials | 69.74 Lk |
| Purchases Raw Materials | 5.65 Cr |
| Closing Raw Materials | 41.76 Lk |
| Other Direct Purchases / Brought in cost | 35.09 Lk |
| Power & Fuel Cost | 70.9 Lk |
| Electricity & Power | 70.9 Lk |
| Employee Cost | 14.51 Cr |
| Salaries, Wages & Bonus | 11.64 Cr |
| Contributions to EPF & Pension Funds | 1.65 Cr |
| Workmen and Staff Welfare Expenses | 63,306 |
| Other Manufacturing Expenses | 94.34 Lk |
| Repairs and Maintenance | 19.58 Lk |
| General and Administration Expenses | 1.93 Cr |
| Rent , Rates & Taxes | 7.84 Lk |
| Insurance | 3.35 Lk |
| Professional and legal fees | 73.8 Lk |
| Traveling and conveyance | 60.72 Lk |
| Selling and Distribution Expenses | 13.51 Lk |
| Advertisement & Sales Promotion | 1.49 Lk |
| Sales Commissions & Incentives | 8.6 Lk |
| Freight and Forwarding | 15,554 |
| Miscellaneous Expenses | 5.01 Lk |
| Loss on foreign exchange fluctuations | 443 |
| Total Expenditure | 23.94 Cr |
| Other Income | 6.38 Lk |
| Interest Received | 6.19 Lk |
| Operating Profit | -11.71 Cr |
| Interest | 125.44 Cr |
| Bank Charges etc | 25,609 |
| PBDT | -137.14 Cr |
| Depreciation | 17.33 Cr |
| Profit Before Taxation & Exceptional Items | -154.47 Cr |
| Profit Before Tax | -154.47 Cr |
| Provision for Tax | -32.76 Cr |
| Deferred Tax | -32.76 Cr |
| Profit After Tax | -121.71 Cr |
| Consolidated Net Profit | -121.71 Cr |
| Profit Balance B/F | -913.28 Cr |
| Appropriations | -1034.99 Cr |
| Other Appropriation | -14.19 Lk |
| Earnings Per Share | -40.82 |
| Adjusted EPS | -40.82 |
STANDALONE PROFIT / LOSS FOR PARENTERAL DRUGS (INDIA) LIMITED
| YEAR | Mar 2021 |
|---|---|
| No of Months | 12 months |
| Gross Sales | 12.17 Cr |
| Sales | 7.82 Cr |
| Job Work/ Contract Receipts | 4.33 Cr |
| Net Sales | 12.17 Cr |
| Increase/Decrease in Stock | -61.54 Lk |
| Raw Material Consumed | 6.28 Cr |
| Opening Raw Materials | 69.74 Lk |
| Purchases Raw Materials | 5.65 Cr |
| Closing Raw Materials | 41.76 Lk |
| Other Direct Purchases / Brought in cost | 35.09 Lk |
| Power & Fuel Cost | 70.9 Lk |
| Electricity & Power | 70.9 Lk |
| Employee Cost | 14.51 Cr |
| Salaries, Wages & Bonus | 11.64 Cr |
| Contributions to EPF & Pension Funds | 1.65 Cr |
| Workmen and Staff Welfare Expenses | 63,306 |
| Other Manufacturing Expenses | 94.34 Lk |
| Repairs and Maintenance | 19.58 Lk |
| General and Administration Expenses | 1.93 Cr |
| Rent , Rates & Taxes | 7.84 Lk |
| Insurance | 3.35 Lk |
| Professional and legal fees | 73.75 Lk |
| Traveling and conveyance | 60.72 Lk |
| Selling and Distribution Expenses | 13.51 Lk |
| Advertisement & Sales Promotion | 1.49 Lk |
| Sales Commissions & Incentives | 8.6 Lk |
| Freight and Forwarding | 15,554 |
| Miscellaneous Expenses | 5.01 Lk |
| Loss on foreign exchange fluctuations | 443 |
| Total Expenditure | 23.94 Cr |
| Other Income | 6.38 Lk |
| Interest Received | 6.19 Lk |
| Operating Profit | -11.71 Cr |
| Interest | 125.44 Cr |
| Bank Charges etc | 21,417 |
| PBDT | -137.14 Cr |
| Depreciation | 17.33 Cr |
| Profit Before Taxation & Exceptional Items | -154.47 Cr |
| Profit Before Tax | -154.47 Cr |
| Provision for Tax | -32.76 Cr |
| Deferred Tax | -32.76 Cr |
| Profit After Tax | -121.71 Cr |
| Consolidated Net Profit | -121.71 Cr |
| Profit Balance B/F | -913.4 Cr |
| Appropriations | -1035.12 Cr |
| Other Appropriation | -14.19 Lk |
| Earnings Per Share | -40.82 |
| Adjusted EPS | -40.82 |
CONSOLIDATED CASH FLOW FOR PARENTERAL DRUGS (INDIA) LIMITED
| Year End | Mar 2021 |
|---|---|
| No of Months | 12 months |
| Profit Before Tax | -154.47 Cr |
| Adjustment | 143.75 Cr |
| Changes In working Capital | 136.05 Cr |
| Cash Flow after changes in Working Capital | 125.32 Cr |
| Cash Flow from Operating Activities | 125.32 Cr |
| Cash Flow from Investing Activities | 6.19 Lk |
| Cash Flow from Financing Activitie | -125.44 Cr |
| Net Cash Inflow / Outflow | -5.11 Lk |
| Opening Cash & Cash Equivalents | 10.81 Lk |
| Closing Cash & Cash Equivalent | 5.7 Lk |
STANDALONE CASH FLOW FOR PARENTERAL DRUGS (INDIA) LIMITED
| Year End | Mar 2021 |
|---|---|
| No of Months | 12 months |
| Profit Before Tax | -154.47 Cr |
| Adjustment | 143.75 Cr |
| Changes In working Capital | 136.05 Cr |
| Cash Flow after changes in Working Capital | 125.32 Cr |
| Cash Flow from Operating Activities | 125.32 Cr |
| Cash Flow from Investing Activities | 6.19 Lk |
| Cash Flow from Financing Activitie | -125.44 Cr |
| Net Cash Inflow / Outflow | -5.03 Lk |
| Opening Cash & Cash Equivalents | 10.72 Lk |
| Closing Cash & Cash Equivalent | 5.7 Lk |
CONSOLIDATED BALANCE SHEET FOR PARENTERAL DRUGS (INDIA) LIMITED
| YEAR | Mar 2021 |
|---|---|
| Share Capital | 29.82 Cr |
| Equity - Authorised | 36.5 Cr |
| Equity - Issued | 29.82 Cr |
| Equity Paid Up | 29.82 Cr |
| Face Value | 10 |
| Total Reserves | -712.69 Cr |
| Securities Premium | 203.71 Cr |
| Capital Reserves | 1 Lk |
| Profit & Loss Account Balance | -1034.85 Cr |
| General Reserves | 8.4 Cr |
| Reserve excluding Revaluation Reserve | -784.75 Cr |
| Revaluation reserve | 72.05 Cr |
| Shareholder's Funds | -682.88 Cr |
| Minority Interest | 12.25 Lk |
| Term Loans - Banks | 565.37 Cr |
| Unsecured Loans | 107.2 Cr |
| Loans - Others | 30 Cr |
| Deferred Tax Assets / Liabilities | -165.83 Cr |
| Deferred Tax Assets | 205.6 Cr |
| Deferred Tax Liability | 39.77 Cr |
| Other Long Term Liabilities | 12 Lk |
| Total Non-Current Liabilities | -58.51 Cr |
| Trade Payables | 7.81 Cr |
| Sundry Creditors | 7.81 Cr |
| Other Current Liabilities | 1125.52 Cr |
| Advances received from customers | 74.62 Cr |
| Interest Accrued But Not Due | 512.75 Cr |
| Short Term Provisions | 10.31 Cr |
| Total Current Liabilities | 1143.64 Cr |
| Total Liabilities | 402.37 Cr |
| Gross Block | 786.36 Cr |
| Less: Accumulated Depreciation | 464.55 Cr |
| Net Block | 321.81 Cr |
| Non Current Investments | 2.4 Cr |
| Long Term Investment | 2.4 Cr |
| Unquoted | 2.4 Cr |
| Long Term Loans & Advances | 7.48 Cr |
| Other Non Current Assets | 2.61 Cr |
| Total Non-Current Assets | 334.3 Cr |
| Unquoted | 2.4 Cr |
| Inventories | 1.59 Cr |
| Raw Materials | 41.76 Lk |
| Finished Goods | 1.17 Cr |
| Cash and Bank | 5.7 Lk |
| Cash in hand | 3,465 |
| Balances at Bank | 5.66 Lk |
| Other Current Assets | 56.7 Cr |
| Short Term Loans and Advances | 9.72 Cr |
| Advances recoverable in cash or in kind | 62.3 Lk |
| Total Current Assets | 68.07 Cr |
| Net Current Assets (Including Current Investments) | -1075.57 Cr |
| Total Assets | 402.37 Cr |
| Contingent Liabilities | 26.28 Cr |
| Total Debt | 635.58 Cr |
| Adjusted Book Value | -253.19 |
STANDALONE BALANCE SHEET FOR PARENTERAL DRUGS (INDIA) LIMITED
| YEAR | Mar 2021 |
|---|---|
| Share Capital | 29.82 Cr |
| Equity - Authorised | 36.5 Cr |
| Equity - Issued | 29.82 Cr |
| Equity Paid Up | 29.82 Cr |
| Face Value | 10 |
| Total Reserves | -713.02 Cr |
| Securities Premium | 203.71 Cr |
| Capital Reserves | 1 Lk |
| Profit & Loss Account Balance | -1034.97 Cr |
| General Reserves | 8.2 Cr |
| Reserve excluding Revaluation Reserve | -785.07 Cr |
| Revaluation reserve | 72.05 Cr |
| Shareholder's Funds | -683.2 Cr |
| Term Loans - Banks | 565.37 Cr |
| Unsecured Loans | 106.24 Cr |
| Loans - Others | 29.04 Cr |
| Deferred Tax Assets / Liabilities | -165.83 Cr |
| Deferred Tax Assets | 205.6 Cr |
| Deferred Tax Liability | 39.77 Cr |
| Other Long Term Liabilities | 12 Lk |
| Total Non-Current Liabilities | -59.48 Cr |
| Trade Payables | 7.81 Cr |
| Sundry Creditors | 7.81 Cr |
| Other Current Liabilities | 1125.52 Cr |
| Advances received from customers | 74.62 Cr |
| Interest Accrued But Not Due | 512.75 Cr |
| Short Term Provisions | 10.31 Cr |
| Total Current Liabilities | 1143.64 Cr |
| Total Liabilities | 400.96 Cr |
| Gross Block | 786.36 Cr |
| Less: Accumulated Depreciation | 464.55 Cr |
| Net Block | 321.81 Cr |
| Non Current Investments | 2.58 Cr |
| Long Term Investment | 2.58 Cr |
| Unquoted | 2.58 Cr |
| Long Term Loans & Advances | 7.48 Cr |
| Other Non Current Assets | 1.74 Cr |
| Total Non-Current Assets | 333.61 Cr |
| Unquoted | 2.58 Cr |
| Inventories | 1.59 Cr |
| Raw Materials | 41.76 Lk |
| Finished Goods | 1.17 Cr |
| Cash and Bank | 5.7 Lk |
| Cash in hand | 3,465 |
| Balances at Bank | 5.66 Lk |
| Other Current Assets | 56.7 Cr |
| Short Term Loans and Advances | 9 Cr |
| Advances recoverable in cash or in kind | 47.05 Lk |
| Total Current Assets | 67.35 Cr |
| Net Current Assets (Including Current Investments) | -1076.29 Cr |
| Total Assets | 400.96 Cr |
| Contingent Liabilities | 135.04 Cr |
| Total Debt | 634.62 Cr |
| Adjusted Book Value | -253.3 |
FINANCIAL RATIOS (CONSOLIDATED) FOR PARENTERAL DRUGS (INDIA) LIMITED
| YEAR | Mar 2021 |
|---|---|
| Operational & Financial Ratios | |
| Earnings Per Share (Rs) | -40.82 |
| CEPS(Rs) | -35.01 |
| Book NAV/Share(Rs) | -253.19 |
| Tax Rate(%) | 21.21 |
| Margin Ratios | |
| Core EBITDA Margin(%) | -96.75 |
| EBIT Margin(%) | -238.63 |
| Pre Tax Margin(%) | -1269.54 |
| PAT Margin (%) | -1000.31 |
| Cash Profit Margin (%) | -857.91 |
| Performance Ratios | |
| ROA(%) | -29.65 |
| Asset Turnover(x) | 0.03 |
| Sales/Fixed Asset(x) | 0.02 |
| Working Capital/Sales(x) | -0.01 |
| Efficiency Ratios | |
| Fixed Capital/Sales(x) | 64.63 |
| Inventory Days | 42.69 |
| Payable days | 507.33 |
| Valuation Parameters | |
| PCE(x) | -0.09 |
| Price/Book(x) | -0.01 |
| EV/Net Sales(x) | 53.01 |
| EV/Core EBITDA(x) | -55.08 |
| EV/EBIT(x) | -22.21 |
| EV/CE(x) | 1.6 |
| M Cap / Sales | 0.78 |
| Growth Ratio | |
| Net Sales Growth(%) | -61.83 |
| Core EBITDA Growth(%) | 18.88 |
| EBIT Growth(%) | 8.64 |
| PAT Growth(%) | -6.7 |
| EPS Growth(%) | -6.7 |
| Financial Stability Ratios | |
| Total Debt/Equity(x) | -0.84 |
| Current Ratio(x) | 0.06 |
| Quick Ratio(x) | 0.06 |
| Interest Cover(x) | -0.23 |
| Total Debt/Mcap(x) | 67.25 |
FINANCIAL RATIOS (STANDALONE) FOR PARENTERAL DRUGS (INDIA) LIMITED
| YEAR | Mar 2021 |
|---|---|
| Operational & Financial Ratios | |
| Earnings Per Share (Rs) | -40.82 |
| CEPS(Rs) | -35.01 |
| Book NAV/Share(Rs) | -253.3 |
| Tax Rate(%) | 21.21 |
| Margin Ratios | |
| Core EBITDA Margin(%) | -96.75 |
| EBIT Margin(%) | -238.62 |
| Pre Tax Margin(%) | -1269.53 |
| PAT Margin (%) | -1000.3 |
| Cash Profit Margin (%) | -857.9 |
| Performance Ratios | |
| ROA(%) | -29.75 |
| Asset Turnover(x) | 0.03 |
| Sales/Fixed Asset(x) | 0.02 |
| Working Capital/Sales(x) | -0.01 |
| Efficiency Ratios | |
| Fixed Capital/Sales(x) | 64.63 |
| Inventory Days | 42.69 |
| Payable days | 507.22 |
| Valuation Parameters | |
| PCE(x) | -0.09 |
| Price/Book(x) | -0.01 |
| EV/Net Sales(x) | 52.93 |
| EV/Core EBITDA(x) | -55.01 |
| EV/EBIT(x) | -22.18 |
| EV/CE(x) | 1.61 |
| M Cap / Sales | 0.78 |
| Growth Ratio | |
| Net Sales Growth(%) | -61.83 |
| Core EBITDA Growth(%) | 18.87 |
| EBIT Growth(%) | 8.63 |
| PAT Growth(%) | -6.7 |
| EPS Growth(%) | -6.7 |
| Financial Stability Ratios | |
| Total Debt/Equity(x) | -0.84 |
| Current Ratio(x) | 0.06 |
| Quick Ratio(x) | 0.06 |
| Interest Cover(x) | -0.23 |
| Total Debt/Mcap(x) | 67.14 |
SHARE HOLDING PATTERN FOR PARENTERAL DRUGS (INDIA) LIMITED
| Date | Jun 2021 | Sep 2021 | Dec 2021 | Mar 2022 |
|---|---|---|---|---|
| Promoters % | 73.28 | 73.28 | 73.28 | 73.29 |
| FII % | 0.00 | 0.00 | 0.00 | 0.00 |
| DII % | 0.00 | 0.00 | 0.00 | 0.00 |
| Public % | 26.71 | 26.71 | 26.71 | 26.71 |
PEER COMPARISON FOR PARENTERAL DRUGS (INDIA) LIMITED
CORPORATE ACTIONS FOR PARENTERAL DRUGS
| Exchange Date | Purpose | Book Closure Dates |
|---|---|---|
| BSE 18-May-2022 | Board Meeting - Audited Results & Inter alia, to consider and approve: 2. The shifting of registered office of the Company within local limits of the city where it is presently situated from 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West) Mumbai -400053 (Maharashtra) to E/210, 2nd Floor, Crystal Plaza, Off New Link Road, Andheri West, Mumbai -400053 (Maharashtra) and other items as per ag... | 30-May-2022 |
| BSE 04-Feb-2022 | Board Meeting - Quarterly Results | 14-Feb-2022 |
| BSE 02-Feb-2022 | Book Closure - E.G.M. | 25-Feb-2022 01-Mar-2022 |
| BSE 31-Jan-2022 | Board Meeting - Inter alia, to consider and approve : 1. The appointment of Independent Director and 2. Tto consider sale, lease or disposal of the whole or substantially the whole of the undertaking of the Company, 3. to convene the Extra-Ordinary General Meeting of the Company and other items as per agenda of the Meeting. | 02-Feb-2022 |
| BSE 03-Nov-2021 | Board Meeting - Quarterly Results | 12-Nov-2021 |
CORPORATE ANNOUNCEMENTS FOR PARENTERAL DRUGS
| Exchange Date | Category File | Description |
|---|---|---|
| BSE 10-Sep-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI (Listing obligation and Disclosure Requirements) Regulations 2015 (Listing Regulations) and in accordance with the requirements of sub-clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we would like to inform that the Twentieth Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Limited the Corporate Debtor was held on Monday 09th September 2024 at 05:30 P.M. |
| BSE 13-Aug-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI(Listing Obligation and Disclosure Requirements) 2015(Listing Regulations) and in accordance with the requirements of the sub-clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we would like to inform that the Nineteenth Meeting of Committee of Creditors ("CoC") of Parental Drugs(India) Limited the Corporate Debtor was held on Monday 12th August 2024 at 2:30 P.M. |
| BSE 10-Aug-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and in accordance with the requirements of sub -clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we wish to inform you that the Nineteenth meeting of Committee of Creditors ("CoC") of Parenteral Drugs (India) Limited the Corporate Debtor is Scheduled to be held on Monday 12th August 2024 at 02:30 P.M. |
| BSE 10-Aug-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations 2015 (Listing Regulations) and in accordance with the requirements of sub-clause16(g) of Para A of Part A of Schedule III of Listing Regulations we would like to inform that the Eighteenth Meeting of Committee of Creditors ("CoC") of Parenteral Drugs (India) Limited the Corporate Debtor was held on Friday 09th August 2024 at 5:30 P.M |
| BSE 09-Aug-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015(Listing Regulations) and in accordance with the requirements of sub-clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we wish to inform you that the Eighteenth meeting of Committee of Creditors ("COC") of Parenteral Drugs (India) Limited the Corporates Debtor is Scheduled to be held on Friday 09th August 2024 at 5:30 P.M. |
| BSE 13-Jul-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and in accordance with the requirements of sub-clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we would like to inform that the Seventeenth Meeting of Committee of Creditors ("CoC") of Parenteral Drugs (India) Limited the Corporate Debtor was held on Friday 12th July 2024 at 05:30 P.M. |
| BSE 12-Jul-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations and in accordance with the requirements of sub- clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we wish to inform you that the Seventeenth meeting of Committee of Creditors ("CoC") of Parentral Drugs (India) Limited the Corporate Debtor is scheduled on Friday 12th July 2024 at 5:30 P.M. |
| BSE 19-Jun-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and in accordance with the requirements of sub- clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we would like to inform that the sixteenth Meeting of Committee of Creditors ("CoC") of Parenteral Drugs (India) Limited the Corporate Debtor was held on Wednesday 19th June 2024 at 5:30 P.M. |
| BSE 18-Jun-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosures Requirements) Regulation 2015 (Listing Regulations) and in accordance with the requirements of sub-clause 16(g) of Para A of Part A of Schedule III of Listing Regulations we wish to inform you that the sixteenth meeting of Committee of Creditors ("CoC") of Parenteral Drugs (India) Limited the Corporate Debtor is scheduled on Wednesday 19th June 2024 at 05:30 P.M. |
| BSE 14-Jun-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Updates - Corporate Insolvency Resolution Process (CIRP) Reply letter With reference to email dated 12.06.2024 regarding Non-disclosure of reasons for delay in submission of financial results for Period/Year ended March 31 2024. |
| BSE 07-Jun-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Dear Madam/Sirs We would like to inform that the Meeting of Committee of Creditors (CoC). pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub- clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations of the Company was held on Friday 07th June 2024 at 6:00 P.M.You are requested to take the above information on record. |
| BSE 06-Jun-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations we would like to inform that the meeting of Committee of Creditors (CoC) of the Company Scheduled for Friday 07th June 2024 at 05:00 PM. |
| BSE 01-Jun-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors We would like to inform that the Meeting of Committee of Creditors (CoC) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations of the Company was held on Wednesday 29th May 2024 at 5:30 P.M. |
| BSE 29-May-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations we would like to inform that the meeting of Committee of Creditors (CoC) of the Company Scheduled for Wednesday 29th May 2024 at 05:30 PM |
| BSE 16-May-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Post-Facto Intimation of the 12th Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Ltd. the Corporate Debtor was held on Tuesday 14th May 2024 at 04:00 PM |
| BSE 14-May-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Prior Intimation of the 12th Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Ltd. the Corporate Debtor Scheduled on Tuesday 14th May 2024 at 04:00 PM. |
| BSE 14-May-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Post-Facto Intimation of the 11th Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Ltd. the Corporate Debtor was held on Saturday 11th May 2024 at 4:00 P.M. |
| BSE 14-May-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Prior Intimation of the 11th Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Ltd. the Corporate Debtor Scheduled on Saturday 11th May 2024 at 04:00 PM. |
| BSE 25-Apr-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors We would like to inform that the Tenth meeting of Committee of Creditors (CoC) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations of the Company was held on Wednesday 24th April 2024 at 3:00 P.M. |
| BSE 25-Apr-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations we would like to inform that the 10th meeting of Committee of Creditors (CoC) of the Company Scheduled for Wednesday 24th April 2024 at 03:00 PM. |
| BSE 02-Apr-2024 | General Announcements FILE | Request For Deletion Of Recently Submitted The Inadvertent Corporate Announcement Regarding Approval Of Resolution Plan In The 9Th Meeting Of Committee Of Creditors ('Coc') Of Parenteral Drugs (India) Limited The Corporate Debtor I am writing to express my sincere apologies for the recent inadvertent filing of an announcement regarding the approval of a resolution plan by the Committee of Creditors (COC). The announcement acknowledgment number is 7049314. Upon investigation it has come to our attention that this announcement was filed due to a technical error while being logged into another companys account. We want to clarify that this announcement is not related to Parenteral Drugs (India) Limited but to a entirely different company. We understand the importance of accurate and timely filings with the Bombay Stock Exchange and we regret any confusion or inconvenience this error may have caused. Rest assured we are taking steps to prevent such incidents from occurring in the future. WE ONCE AGAIN CLARIFY THAT THE CORPORATE DEBTOR HAS NOT EVEN REACHED TO THE STAGE OF RECEIPT OF RESOLUTION PLAN. We apologize for any inconvenience caused and appreciate your understanding in this matter. |
| BSE 02-Apr-2024 | General Announcements FILE | Approval Of Resolution Plan By COC Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and in accordance with the requirements of sub- clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations we wish to inform you that the Committee of Creditors (CoC) of Parenteral Drugs (India) Limited the Corporate Debtor in its 9th meeting approved the resolution plan of the Corporate Debtor. Further the resolution plan is being filed with NCLT Ahmedabad for approval |
| BSE 30-Mar-2024 | Intimation FILE | Closure of Trading Window We wish to inform you that pursuant to the provisions of the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations 2015 as amended and the Companys Code of Conduct for Prohibition of Insider Trading Trading Window for dealing in the shares of the Company will be closed from Monday April 01 2024 till 48 hours after the announcement of Financial Results for the Quarter / year ended March 31 2024 for all promoters directors officers other designated persons Connected Persons and their immediate relatives. |
| BSE 28-Mar-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors We would like to inform that the sixth meeting of Committee of Creditors (CoC) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations of the Company was held on Tuesday 26th March 2024 at 03:00 PM. |
| BSE 15-Mar-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors We would like to inform that the sixth meeting of Committee of Creditors (CoC) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations of the Company was held on Thursday 14th March 2024 at 05:00 PM. |
| BSE 13-Mar-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Prior Intimation of the 8th Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Ltd. the Corporate Debtor Scheduled on Thursday 14th March 2024 at 05:00 PM. |
| BSE 27-Feb-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Post-Facto Intimation of the Seventh Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Ltd. the Corporate Debtor was held on Friday 16th February 2024 at 02:30 PM. |
| BSE 23-Jan-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Public Announcement Post-Facto Intimation of the publication of Form G of Parenteral Drugs (India) Ltd. the Corporate Debtor which was published on Sunday 21st January 2024 |
| BSE 20-Jan-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors Post-Facto Intimation of the Sixth Meeting of Committee of Creditors (CoC) of Parenteral Drugs (India) Ltd. the Corporate Debtor was held on Friday 19th January 2024 at 12:00 Noon |
| BSE 16-Jan-2024 | General Announcements FILE | Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors We would like to inform that the fifth meeting of Committee of Creditors (CoC) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations of the Company was held on Monday 15th January 2024 at 03:00 P.M. |
INSIDER TRADING FOR PARENTERAL DRUGS
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Insider trading details found | |||
BULK BLOCK DEALS FOR PARENTERAL DRUGS (INDIA) LIMITED
| Exchange Dates | Activity | Qty & Price (%) | Person / Organisation |
|---|---|---|---|
| No Bulk Block details found | |||
DIVIDEND BY PARENTERAL DRUGS (INDIA) LIMITED
No dividend details found
SPLIT / BONUS BY PARENTERAL DRUGS (INDIA) LIMITED
No Split / Bonus details found
Data feed Source : www.accordfintech.com, NSE DATA Feed & BSE Data Feed
